Panagora Asset Management Inc. Purchases 65,828 Shares of United Therapeutics Corporation $UTHR

Panagora Asset Management Inc. increased its stake in United Therapeutics Corporation by 340.8% in Q2, owning 85,143 shares worth $24.47 million. Analysts have set new price targets, with a consensus rating of "Moderate Buy" and an average target price of $505.00. Insiders sold shares worth $244 million in the last three months. United Therapeutics' stock opened at $479.95, with a market cap of $20.67 billion.

Panagora Asset Management Inc. boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 340.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,143 shares of the biotechnology company's stock after purchasing an additional 65,828 shares during the period. Panagora Asset Management Inc. owned about 0.19% of United Therapeutics worth $24,466,000 as of its most recent SEC filing.

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Avantax Advisory Services Inc. boosted its position in shares of United Therapeutics by 226.5% during the first quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company's stock valued at $596,000 after buying an additional 1,341 shares during the period. LPL Financial LLC lifted its stake in shares of United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of United Therapeutics during the 1st quarter worth approximately $313,000. Arkadios Wealth Advisors purchased a new position in United Therapeutics during the 1st quarter valued at $301,000. Finally, US Bancorp DE grew its position in United Therapeutics by 12.2% in the 1st quarter. US Bancorp DE now owns 1,971 shares of the biotechnology company's stock valued at $608,000 after acquiring an additional 215 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Get United Therapeutics alerts:

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. Wells Fargo & Company lifted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 30th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 10th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Oppenheimer upped their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $505.00.

Liquidia: Court victory the awakening of an industry giant?

Get Our Latest Stock Report on United Therapeutics

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction on Monday, November 24th. The stock was sold at an average price of $473.66, for a total transaction of $10,657,350.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 21,000 shares of the firm's stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $473.64, for a total value of $9,946,440.00. Following the sale, the chief financial officer directly owned 8,142 shares in the company, valued at approximately $3,856,376.88. The trade was a 72.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 556,935 shares of company stock worth $244,015,177 in the last three months. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

NASDAQ UTHR opened at $479.95 on Tuesday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $492.62. The company has a market capitalization of $20.67 billion, a price-to-earnings ratio of 18.19, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. The company's 50-day simple moving average is $448.96 and its two-hundred day simple moving average is $363.80.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts' expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company's revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.39 EPS. Equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here